


For adult patients with  
opioid-induced constipation (OIC)

## Your guide to prescribing RELISTOR



# Take a proactive approach to OIC with RELISTOR<sup>1</sup>

## INDICATIONS

- RELISTOR® (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.
- RELISTOR injection is also indicated for the treatment of OIC in adults with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care

## IMPORTANT SAFETY INFORMATION

- RELISTOR tablets and injection are contraindicated in patients with known or suspected mechanical gastrointestinal obstruction and patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.
- Cases of gastrointestinal perforation have been reported in adult patients with opioid-induced constipation and advanced illness with conditions that may be associated with localized or diffuse reduction of structural integrity in the wall of the gastrointestinal tract (e.g., peptic ulcer disease, Ogilvie's syndrome, diverticular disease, infiltrative gastrointestinal tract malignancies or peritoneal metastases). Take into account the overall risk-benefit profile when using RELISTOR in patients with these conditions or other conditions which might result in impaired integrity of the gastrointestinal tract wall (e.g., Crohn's disease). Monitor for the development of severe, persistent, or worsening abdominal pain; discontinue RELISTOR in patients who develop this symptom.

Please see additional Important Safety Information throughout  
and full Prescribing Information in pocket.

Take a proactive approach:  
Choose RELISTOR for your adult  
patients with OIC

**RELISTOR tablets,  
for at-home  
convenience<sup>1</sup>**

150 mg tablets



**ICD-10-CM codes that can  
be considered for OIC<sup>2\*</sup>**

**K59.03 Drug-induced constipation**

## Dosing recommendations

### For adult patients with chronic non-cancer pain (CNCP)<sup>1</sup>

Once daily in the morning	Three (3) 150 mg tablets	450 mg total
------------------------------	-----------------------------	--------------

**RELISTOR tablets should be taken with water on an empty stomach at least 30 minutes before the first meal of the day.**

A dosage reduction of RELISTOR tablets to 150 mg, once daily in the morning, is recommended in patients with moderate and severe renal impairment or patients with moderate or severe hepatic impairment.

RELISTOR therapy should be continued only during opioid use.

\*The ICD-10-CM codes and all other patient access-related information are provided for informational purposes only. It is the treating physician's responsibility to determine the proper diagnosis, treatment, and applicable ICD-10-CM code. Salix does not guarantee coverage or reimbursement for the product.

## IMPORTANT SAFETY INFORMATION (continued)

- If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their healthcare provider.

Please see additional Important Safety Information throughout and full Prescribing Information in pocket for more information on dosing and administration with RELISTOR.

PI in pocket.

## **RELISTOR subcutaneous injection: For inpatient or outpatient use<sup>1</sup>**

Available as 8 mg and 12 mg pre-filled syringes and 12 mg single-dose vial



**K59.00 Constipation, unspecified**

**K59.09 Other constipation**

## Dosing recommendations<sup>†</sup>

### For adult patients with CNCP<sup>1</sup>

Once daily subcutaneous injection	12 mg syringes	12 mg dose
---	----------------	------------

### For adult patients with advanced illness and active cancer<sup>‡</sup> pain<sup>1</sup>

WEIGHT OF ADULT PATIENT	SUBCUTANEOUS DOSE, QOD <sup>§</sup>	INJECTION VOLUME
<38 kg or >114 kg	0.15 mg/kg	See below <sup>  </sup>
38 kg to <62 kg	8 mg	0.4 mL
62 kg to 114 kg	12 mg	0.6 mL

<sup>†</sup>In patients who require opioid dosage escalation for palliative care.

QOD, every other day.

<sup>‡</sup>A dosage reduction of RELISTOR injection is recommended in patients with moderate and severe renal impairment and in patients with severe hepatic impairment. See full Prescribing Information for details.<sup>1</sup>

<sup>§</sup>Up to once daily as needed.<sup>1</sup>

<sup>||</sup>Calculate the injection volume for these patients by multiplying the patient weight in kilograms by 0.0075 and then rounding up the volume to the nearest 0.1 mL.<sup>1</sup>

**RELISTOR<sup>®</sup>**  
methylnaltrexone bromide  
Tablets & Subcutaneous Injection

## IMPORTANT SAFETY INFORMATION (continued)

- Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, and yawning have occurred in patients treated with RELISTOR. Patients having disruptions to the blood-brain barrier may be at increased risk for opioid withdrawal and/or reduced analgesia and should be monitored for adequacy of analgesia and symptoms of opioid withdrawal.
- Avoid concomitant use of RELISTOR with other opioid antagonists because of the potential for additive effects of opioid receptor antagonism and increased risk of opioid withdrawal.
- The use of RELISTOR during pregnancy may precipitate opioid withdrawal in a fetus due to the immature fetal blood-brain barrier and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because of the potential for serious adverse reactions, including opioid withdrawal, in breastfed infants, advise women that breastfeeding is not recommended during treatment with RELISTOR. In nursing mothers, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
- A dosage reduction of RELISTOR tablets and RELISTOR injection is recommended in patients with moderate and severe renal impairment (creatinine clearance less than 60 mL/minute as estimated by Cockcroft-Gault). No dosage adjustment of RELISTOR tablets or RELISTOR injection is needed in patients with mild renal impairment.
- A dosage reduction of RELISTOR tablets is recommended in patients with moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment. No dosage adjustment of RELISTOR tablets is needed in patients with mild hepatic impairment (Child-Pugh Class A). No dosage adjustment of RELISTOR injection is needed for patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, monitor for methylnaltrexone-related adverse reactions and dose adjust per Prescribing Information as may be indicated.
- In the clinical studies, the most common adverse reactions were:

### OIC in adult patients with chronic non-cancer pain

- RELISTOR tablets ( $\geq$  2% of RELISTOR patients and at a greater incidence than placebo): abdominal pain (14%), diarrhea (5%), headache (4%), abdominal distention (4%), vomiting (3%), hyperhidrosis (3%), anxiety (2%), muscle spasms (2%), rhinorrhea (2%), and chills (2%).
- RELISTOR injection ( $\geq$  1% of RELISTOR patients and at a greater incidence than placebo): abdominal pain (21%), nausea (9%), diarrhea (6%), hyperhidrosis (6%), hot flush (3%), tremor (1%), and chills (1%).

### OIC in adult patients with advanced illness

- RELISTOR injection ( $\geq$  5% of RELISTOR patients and at a greater incidence than placebo): abdominal pain (29%), flatulence (13%), nausea (12%), dizziness (7%), and diarrhea (6%).

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

**Please see additional Important Safety Information throughout and full Prescribing Information in pocket.**

**REFERENCES:** 1. RELISTOR [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals. 2. Centers for Medicare and Medicaid Services. Information partners can use on: Medicare Drug Coverage under Medicare Part A, Part B, Part C, & Part D. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56632&ver=23&>. Accessed October 24, 2024.



[www.salix.com](http://www.salix.com)

400 Somerset Corporate Boulevard Bridgewater, NJ 08807

Tel 800-321-4576

Relistor is a trademark of Salix Pharmaceuticals or its affiliates.

©2024 Salix Pharmaceuticals or its affiliates. REL.0122.USA.24

**RELISTOR®**  
methylnaltrexone bromide  
Tablets & Subcutaneous Injection